聯合光電(300691.SZ):“高端光電鏡頭產品智能製造基地擴建項目”結項
格隆匯 3 月 17日丨聯合光電(300691.SZ)公佈,公司於2021年3月17日召開的第三屆董事會第一次會議、第三屆監事會第一次會議審議通過關於《募投項目結項並將節餘募集資金永久補充流動資金》的議案,同意公司2017年首次公開發行股票募集資金投資項目“高端光電鏡頭產品智能製造基地擴建項目”結項,並將節餘募集資金2019.69萬元(包含尚未支付的設備尾款和扣除銀行手續費的利息收入、理財收益,實際金額以資金轉出當日專户餘額為準)全部轉入公司基本存款賬户用於永久補充公司流動資金,同時註銷對應的募集資金賬户。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.